Viridian Therapeutics Inc. (NASDAQ:VRDN) reported positive Phase 1 clinical trial results for VRDN-008, highlighting its pharmacokinetic and pharmacodynamic profile as a potential best-in-class subcutaneous treatment for autoimmune and rare diseases.
The biotechnology company confirmed the investigational therapy sustained IgG antibody reduction through eight weeks, supporting a transformative dosing schedule of once every eight weeks for future patients.
• Viridian Therapeutics stock is showing exceptional strength. What’s behind VRDN gains?
Phase 1 Trial Highlights Extended Half-Life and IgG Suppression
The Phase 1 clinical study evaluated subcutaneous VRDN-008 in healthy volunteers who received two subcutaneous doses, one at trial initiation and a second dose at week four.
VRDN-008, a bifunctional FcRn inhibitor licensed from Paragon Therapeutics, integrates an Fc fragment with an albumin-binding domain to prolong antibody suppression.
Clinical findings showed VRDN-008 achieved an extended half-life of 15 to 18 days, lasting up to six times longer than first-generation Fc fragments.
The candidate produced deep and prolonged IgG suppression, achieving a 74% IgG reduction at peak levels across the eight-week post-dosing period.
VRDN-008 also demonstrated a favorable safety profile that spared albumin and LDL cholesterol, with healthy volunteers reporting no serious adverse events or dose-limiting toxicities during the study.
Wearable On-Body Device Enables At-Home Administration
Viridian plans to administer subcutaneous VRDN-008 using the Enable enFuse wearable delivery device developed by Enable Injections.
This hands-free, on-body injector operates with a single button press, representing the next generation of drug delivery to simplify at-home self-administration.
Viridian secured exclusive global rights to enFuse for FcRn-targeted therapies in January 2023.
Registrational Study Targets Mid-2027 Launch In MG
Encouraged by the Phase 1 outcomes, Viridian plans to advance VRDN-008 rapidly into pivotal development to establish a direct path toward a Biologics License Application.
Pending feedback from regulatory authorities, the company aims to initiate at least one registrational trial in mid-2027, starting with myasthenia gravis.
The multi-arm registrational trial will deliver VRDN-008 through the enFuse system and evaluate four-week and eight-week dosing regimens against placebo.
Viridian also plans to expand VRDN-008 development into multiple autoantibody-mediated autoimmune diseases beyond myasthenia gravis.
VRDN Price Action: Viridian Therapeutics shares were up 4.69% at $29.83 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.




